Remsima™ - The first biosimilar infliximab;Remsima™- První biosimiĺaŕni infliximab

Gastroenterologie a Hepatologie

Volumn 68, Issue 2, 2014, Pages 178-179

  Lukas M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ARTICLE;

EID: 84901196432     PISSN: 18047874     EISSN: 1804803X     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Urbánek K. První biosimilární monoklonální protilátka - infliximab. Klin Farmakol Farm 2014; 28(1): 19-22.
2. Park W, Hrycaj P, Jeka S et al. A randomised, double-blind, multicentre parallel-group, prospective study comparing the pharmacokinetics, safety and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study. Ann Rheum Dis 2013; 72(10): 1605-1612. doi: 10.1136/annrheumdis-2012-203091.
3. Yoo DH, Hrycaj P, Miranda P et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72(10): 1613-1620. doi: 10.1136/annrheumdis-2012-203090.
4. SÚKL. Souhrn údajů o přípravku Remsima. Dostupné z: http://www.sukl.cz/modules/medication/detail.php?code= 0194345&tab=texts.